This content is only available as a PDF.

Author notes

Current affiliation: Novartis

Disclaimer: This research was supported [in part] by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH author(s) were made as part of their official duties as NIH federal employees, are in compliance with agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.

Article PDF first page preview

First page of Late effects following CAR T-cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia

Supplemental data